

BRITISH THORACIC SOCIETY WINTER MEETING 2026

Wednesday 25 to Friday 27 November 2026, QEII Centre, London

PROVISIONAL PROGRAMME SYMPOSIA, GUEST LECTURES & JOURNAL CLUBS

Wednesday 25 November 2026

08.00 – 09.00

REGISTRATION & REFRESHMENTS

08.30 – 09.00

JOURNAL CLUB

COUGH

Chaired by: Dr Barnaby Hirons (London)

Learning objectives:

To review the latest publications and evidence in the field of cough

09.00 – 10.30

SYMPOSIUM

THE CHANGING BRONCHIECTASIS LANDSCAPE: INFECTION, BIOLOGICS AND ANTI-INFLAMMATORIES

Chaired by: Professor Melissa McDonnell (Galway) and Dr Phil Mitchelmore (Exeter)

09.00 How the microbial community impacts on immune responses in bronchiectasis
Professor Sanjay Chotirmal (Singapore)

09.30 Monoclonal antibodies to target *Pseudomonas aeruginosa*: What have we learnt
from the GREAT trials and mechanistic studies?
Dr Merete Long (Oxford)

10.00 Targeting Type 2 inflammation in Bronchiectasis: Lessons from MAHALE
Professor Stefano Aliberti (Italy)

Learning objectives:

1. Understanding of translational science and mycobiome/ resistome and microbiome. Novel data on gut-lung axis resistome in bronchiectasis
 2. New study data on *pseudomonas* virulence and targeting in bronchiectasis using non-antibiotics. New data on bacterial clearance and patient quality of life using anti-microbial monoclonal antibodies
 3. Understand study design and limitations / strengths and role of biologics to date in bronchiectasis. Data from clinical trials (not presented before) on biologics in bronchiectasis will be discussed
-

09.00 – 10.30

SYMPOSIUM

ASTHMA GOING VIRAL

Chaired by: Dr Tom Fardon (Dundee) and Dr Ran Wang (Manchester)

- 09.00 The interplay between viruses and childhood asthma inception
Professor James Gern (USA)
- 09.30 Asthma exacerbations and viruses: what we have learnt from the bench
Professor Sebastian Johnston (London)
- 10.00 Asthma exacerbations and viruses: what we have learnt from the bedside
Professor David Jackson (London)

Learning objectives:

1. To understand the role of respiratory viruses in the inception and pathogenesis of asthma
 2. To review the latest mechanistic insights from experimental and translational models exploring the pathophysiology of virus-induced asthma exacerbations
 3. To understand current and novel strategies to limit the impact of respiratory viruses in patients at risk of severe asthma exacerbations
-

09.00 – 10.30

SYMPOSIUM

JOINT BTS/BALR SYMPOSIUM (Part 1)

PIONEERING NEW FRONTIERS IN RESPIRATORY RESEARCH: THE BIG DATA REVOLUTION

Chaired by: Dr Manuela Plate (London) and Dr Kirsty McGee (Birmingham)

- 09.00 The power of data integration to progress medical research: lessons from outside the lung
Professor John Terry (Plymouth)
- 09.30 Applying AI and deep learning to detect lung disease
Professor Liangxiu Han (Manchester)
- 10.00 Single cell spatial biology reveals early immune events in lung disease
Professor Ling-Pei Ho (Oxford)

Learning objectives:

1. Understand the power of data integration across technologies with mathematical modelling to progress translational medical research
 2. Recognise the power of AI and deep learning applications in the diagnosis, monitoring and prediction of chronic respiratory diseases
 3. Understand how we use new big data techniques in discovering what matters for patients – defining early immune events means possible therapeutic targets
-

09.00 – 10.30

SYMPOSIUM

GENES, THE ENVIRONMENT AND WORKPLACE EXPOSURES

Chaired by: Dr Huda Badri (Manchester) and Dr Clare Burton (Sheffield)

- 09.00 Emerging epidemiology of asthma related to work
Oriane Dumas (France)
- 09.30 From exposure science to policy in silica-related lung disease
Dr David Fishwick (Sheffield)
- 10.00 The air we share: short and long-term impacts of air quality on airway diseases
Anna Hansell (Leicester)

Learning objectives:

1. Understand how genetic susceptibility interacts with airborne occupational and environmental exposures to influence risk and outcomes for respiratory disease, including lung cancer and COPD
 2. Examine current epidemiological and mechanistic evidence linking indoor and outdoor air quality with chronic airway disorders
 3. Explore how exposure science and real-world surveillance are driving change in how we detect, regulate and prevent silica-related lung disease
-

10.45am – 12.15pm

SYMPOSIUM

TARGETING COPD: FROM MECHANISTICS TO THERAPEUTICS

Chaired by: Dr Neil Greening (Leicester) and Dr Nicola Smallcombe (London)

- 10.45 From mechanism to medicine: pathways for targeted therapy in COPD
Professor Francesca Polverino (USA)
- 11.15 Should we focus on alarmins in COPD treatment?
Professor Chris Brightling (Leicester)
- 11.45 Biologics in COPD: what the new BTS clinical statement means for practice
Dr Anthony Martinelli (Cambridge)

Learning objectives:

1. To understand how advances in COPD pathophysiology are shaping the development of targeted therapies
 2. To assess the potential of alarmins as therapeutic targets in COPD
 3. To review how the latest BTS guidance informs the practical use of biologics in COPD care
-

10.45am – 12.15m

SYMPOSIUM

BTS STRATEGY: UK TRANSFORMATION PLANS

10.45am – 12.15pm

SYMPOSIUM

WHAT'S NEW IN ACUTE RESPIRATORY FAILURE?

Chaired by: Dr Ben Messer (Newcastle) and Ema Swingwood (Bristol)

- 10.45 Novel therapeutic agents in ARDS
Professor Daniel McAuley (Belfast)
- 11.15 Biomarker-Driven Stratification and Management for Sepsis in Critical Care
Professor Manu Shanker-Hari (London)
- 11.45 Beyond Survival: Airway Clearance and Recovery
Dr Bronwen Connolly (Belfast)

Learning objectives:

1. Describe major pathways of lung repair and maladaptive remodelling, and how these can lead to persistent dysfunction or fibrosis after injury
2. Discuss the latest in evidence-based precision medicine in critical care
3. The role of chest physiotherapy, mechanical insufflation: exsufflation and pharmacotherapy

13.15 – 14.00

GUEST LECTURE

THE BTS SCIENTIFIC LECTURE

Mediating best immune responses: which is greatest the nose or the lung?

Professor Daniela Ferreira (Oxford)

14.15 – 15.45

SYMPOSIUM

THE MIKE MORGAN LEGACY - PRIORITISING RESPIRATORY CARE & DELIVERING THE NHS LONG TERM PLAN

Chaired by: Professor Michael Steiner (Leicester) and Professor Richard Russell (London)

- 14.15 Enabling early and accurate diagnosis of respiratory disease
Professor William Man (London)
- 14.45 Expanding Pulmonary Rehabilitation
Professor Sally Singh (Leicester)
- 15.15 Digital transformation in respiratory medicine
Dr Jonathan Fuld (Cambridge)

Learning objectives:

1. To recognise the contribution of Prof Morgan in championing this area, the importance of enabling early and accurate diagnosis of respiratory disease and where we are now in achieving the aims of the Long Term Plan
2. To recognise the contribution of Prof Morgan in championing this area, the importance of expanding pulmonary rehabilitation and where we are in achieving the aims of the Long Term Plan

3. To recognise the contribution of Prof Morgan in championing this area, the importance of expanding pulmonary rehabilitation and where we are in achieving the aims of the Long Term Plan

14.15 – 15.45

JOINT BTS/BPRS SYMPOSIUM

BREATHING FROM THE START: THE IMPACT OF AIR POLLUTION ON RESPIRATORY HEALTH FROM BIRTH TO ADOLESCENCE

Chaired by: Dr Sonal Kansra (Sheffield) and Dr Alexandra Adams (Leeds)

14.15 From Womb to Childhood: Biological Mechanisms Linking Air Pollution Exposure to Lung Development and Disease
Professor Pia Hardelid (London)

14.45 Indoor Air Pollution and Child Respiratory Health: Hidden Exposures, Mechanisms, and Modifiable Risks
Dr Shamil Haroon (Birmingham)

15.15 From Evidence to Action: Health Policy Levers to Reduce the Respiratory Impact of Air Pollution in Children
Dr Abigail Whitehouse (London)

Learning objectives:

1. Describe how air pollution exposure from pregnancy through childhood affects lung development and later respiratory disease
 2. Identify key indoor air pollution exposures and modifiable risks relevant to paediatric respiratory health
 3. Understand how air pollution evidence informs policy actions to reduce respiratory health inequalities
-

14.15 – 15.45

SYMPOSIUM

JOINT BTS/BALR/A+LUK EARLY CAREER INVESTIGATOR AWARDS

To be selected from abstracts

16.15 – 16.45

BTS AWARD PRESENTATIONS

16.45 – 17.30

BTS PRESIDENT'S ADDRESS

Professor Robina Coker (London)

17.30 – 18.05

BRITISH THORACIC SOCIETY ANNUAL GENERAL MEETING *(BTS members only)*

Thursday 26 November 2026

08.00 – 09.00

REGISTRATION & REFRESHMENTS

08.30 – 09.00

JOURNAL CLUB**PULMONARY EMBOLISM**

Chaired by: Dr Elaine Soon (Cambridge)

Learning objectivesTo review the latest publications and evidence in the field of PE

09.00 – 10.30

SYMPOSIUM**LUNG CANCER IN NEVER SMOKERS; HOW CAN WE IDENTIFY THOSE AT HIGHEST RISK?**

Chaired by: Professor Mat Callister (Leeds) and Dr Tanya Patrick (London)

09.00 Genetic drivers of non-smoking lung cancers
Dr Marie Theresa Landi (USA)09.30 Understanding and integrating environmental and inherited risk
Dr Frank McCaughan (Cambridge)10.00 How do we identify high risk people? Biomarkers, risk profiling and screening
Dr Hillary Robbins (Lyon)**Learning objectives:**

1. To understand the key genetic drivers of lung cancer in never-smokers, understand how these differ from smoking-related disease, and recognise the clinical implications for diagnosis and treatment pathways
 2. To describe the distinctive features of the tumour micro-environment in lung cancer in never-smokers, including inflammatory pathways and immune cell interactions, and understand their implications for tumour development, progression and treatment
 3. To understand current and emerging approaches to risk stratification in never-smokers, including the role of biomarkers and risk prediction models, with reference to the principles of screening, balancing benefit against harm and maximising mortality benefit
-

09.00 – 10.30

SYMPOSIUM**EVOLVING PRACTICE IN THE DELIVERY OF PULMONARY REHABILITATION: WHERE NEXT?**

Chaired by: Dr Samantha Kon (London) and Dr Enya Daynes (Leicester)

09.00 Delivering effective PR with minimal equipment

Dr Claire Nolan (London)

09.30 Adapting exercise prescription for clinically relevant co-morbidities
Professor Frits Franssen (Netherlands)

10.00 New horizons in exercise training in patients with severe dyspnoea
Professor Ioannis Vogiatzis (Northumbria)

Learning objectives:

1. To understand how pulmonary rehabilitation can be adapted where there is a lack of access to specialized gym equipment and increase accessibility
 2. To review the evidence and provide practical recommendations for tailoring exercise interventions in individuals with COPD and relevant comorbidities
 3. Reviewing the latest evidence and practical implications for the prescription of exercise in those with severe dyspnoea
-

09.00 – 10.30

SYMPOSIUM

JOINT BTS/BALR (PART 2)

PIONEERING NEW FRONTIERS IN RESPIRATORY RESEARCH: THE BIG DATA REVOLUTION

Chaired by: Dr Jonathan Baker (London) and Dr Bettina Schock (Belfast)

09.00 Multi-omics and data integration in translational respiratory research
Dr Iain Stewart (London)

09.30 Integrative 'omic analyses to delineate fibrogenesis
Dr Janine Gote-Schniering (Switzerland)

10.00 Multi-layer network analysis for COPD stratification
Professor Rosa Faner (Spain)

Learning objectives:

1. Discover approaches to integrate multi-omic datasets across respiratory diseases to progress basic, translational, and clinical respiratory research
 2. Understand the molecular insights in to fibrosing lung diseases resulting from multi-omic approaches
 3. Learn how multilayer network analysis can be applied to disease stratification
-

10.45 – 12.30

SYMPOSIUM

PLENARY SCIENTIFIC

Chaired by: Professor Mona Bafadhel (London) and Professor Nick Maskell (Bristol)

10.45 How to SELF-BREATHE
Dr Charles Reilly (London)

- 11.10 Adaptability of the Neutrophil
 Dr Emily Watts (Edinburgh)
- 11.35 Repairing the lung
 Professor Chris Lucas (Edinburgh)
- 12.00 Improving cancer outcomes through early diagnosis
 Dr Anna Bibby (Bristol)

Learning objectives:

1. To enhance understanding of non pharmacological approaches to breathlessness self management, and to introduce SELF-BREATHE, a co designed digital intervention developed to improve patients' confidence and capability in managing breathlessness
 2. To learn about new diagnostic approaches and strategies to increase early detection in lung cancer and mesothelioma
-

13.00 – 13.45

GUEST LECTURE

BTS CLINICAL LECTURE

TIMING IS EVERYTHING: WHAT HIV HAS TAUGHT US ABOUT WHEN TO TREAT

Professor Marc Lipman (London)

Chaired by Professor Adam Hill (Edinburgh)

14.15 – 15.45

SYMPOSIUM

BREATHING DANGER: COPD BEYOND TOBACCO

Chaired by: Professor Sarah Walmsley (Edinburgh) and Dr Marie Fisk (Cambridge)

- 14.15 Mechanistic insights into vaping and e-cigarette exposure in COPD
 Professor Aaron Scott (Birmingham)
- 14.45 What are the multidimensional effects of cannabis smoking on the lung?
 Professor Janice Leung (Canada)
- 15.15 Air pollution as a driver of COPD
 Professor John Hurst (London)

Learning objectives:

1. To understand the cellular and molecular mechanisms by which vaping and e-cigarette exposure contribute to COPD pathogenesis
 2. To evaluate the respiratory effects of cannabis smoking and its role in development and progression of COPD
 3. To understand how air pollution contributes to the development, exacerbation and global burden of COPD
-

14.15 – 15.45

SYMPOSIUM
HIGHLIGHTS FROM THORAX/LANCET RESPIRATORY MEDICINE
Details to be confirmed

14.15 – 15.45
SYMPOSIUM
JOINT BTS/A+LUK/BALR MID-CAREER LECTURES
To be selected from abstracts

16.15 – 17.45
SYMPOSIUM
MALIGNANT PLEURAL EFFUSION – FROM BIOLOGY TO OUTCOMES

Chaired by: Professor Kevin Blyth (Glasgow) and Dr Eleanor Mishra (Norfolk and Norwich)

16.15 The biological effects of pleural fluid on malignant progression - translational evidence on mechanism
Dr Dinesh Addala (Oxford)

16.45 Changing the paradigm for IPCs and Thoracoscopy- the AMPLE 3 RCT results
Prof Gary Lee (Australia)

17.15 Outcomes in randomised trials of malignant effusion - core outcomes and patient priorities
Alexandra Dipper (Bristol)

Learning objectives

1. To understand the current scientific evidence on pleural fluid biological effects on malignant growth
 2. To review evidence on optimal treatment of MPE including surgical options on the basis of RCT data
 3. To review best outcomes in clinical trials of malignant effusion, and how these should be applied in clinical practice
-

16.15 – 17.45
SYMPOSIUM
JOINT BTS/BPRS SYMPOSIUM
SMART LUNGS, SMART CARE: THE PRESENT AND FUTURE OF DIGITAL HEALTH IN PAEDIATRIC RESPIRATORY DISEASE

Chaired by: Dr Hazel Evans (Southampton) and Dr Don Urquhart (Edinburgh)

16.15 Digital Monitoring in Paediatric Sleep and Long-Term Ventilation: Transforming Assessment, Adherence, and Outcomes
Dr Hui Leng Tan (London)

- 16.45 Smart Monitoring in Childhood Asthma and Bronchiectasis: From Early Detection to Personalised Care
Dr Prasad Nagakumar (Birmingham)
- 17.15 From Innovation to Implementation: challenges in implementing Digital Respiratory Technologies into Routine Paediatric Practice
Professor Heather Elphick (Sheffield)

Learning objectives:

1. Understand how digital technologies are used to monitor paediatric respiratory disease, sleep, and long-term ventilation
 2. Evaluate the clinical value of remote monitoring for early detection and personalised management
 3. Identify key challenges and enablers for implementing digital respiratory technologies in routine paediatric practice
-

16.15 – 17.45

SYMPOSIUM

THE PHYSIOLOGY OF DYSPNOEA AND WHY PATIENTS FEEL WHAT THEY FEEL

Chaired by: Dr Karl Sylvester (Cambridge) and Dr Helen Ward (Wolverhampton)

- 16.15 How the brain constructs dyspnoea
Dr Kyle Pattinson (Oxford)
- 16.45 Insights from exercise and disease
Paul Burns (Glasgow)
- 17.15 From sensation to intervention
Dr Lucy Speakman (Oxford)

Learning objectives

1. Understand that disorders of respiratory control are implicated in a wide range of diseases such as COPD, asthma, sleep apnoea and sudden infant death syndrome to name a few
 2. Be knowledgeable in the use of exercise in the assessment of diseases associated with dyspnoea
 3. Understand how the science behind breathlessness then translates into intervention and improved clinical outcomes including quality of life
-
-

17.45 – 19.00

THE PRESIDENT'S RECEPTION – ALL WELCOME!

Friday 27 November 2026

08.00 – 09.00

REGISTRATION & REFRESHMENTS

08.30 – 09.00

JOURNAL CLUB**NTM**

Chaired by Dr Pranab Halder (Leicester)

Learning objectivesTo review the latest publications and evidence in Nontuberculous mycobacteria (NTM)

09.00 – 10.30

SYMPOSIUM**FINDING YOUR NICHE: CELLULAR HETEROGENEITY IN ASTHMA**

Chaired by: Professor Liam Heaney (Belfast) and Dr Maisha Jabeen (Oxford)

- 09.00 Overcrowding in the asthmatic airway: the consequences of bronchospasm
Professor Jody Rosenblatt (London)
- 09.30 Greater than the sum of their parts: Mast cell – eosinophil interactions in asthma
Professor Sven-Erik Dahlén (Sweden)
- 10.00 Upside down: Epithelial responses to eosinophil targeting
Dr Hitasha Rupani (Southampton)

Learning objectives:

1. To understand the mechanobiological effects of bronchoconstriction on the airway epithelium, and how these processes may contribute to airways remodelling in asthma
 2. To explore the role of mast cells in asthma immunopathology and how bidirectional interactions with eosinophils impact the effector function of both cells
 3. To understand how targeting the downstream IL-5/eosinophil pathway may lead to improvements in upstream epithelial function in asthma
-

09.00 – 10.30

SYMPOSIUM**WHEN AUTOIMMUNITY TARGETS THE LUNG**

Chaired by: Dr Katie Ward (London) and Dr Rahul Mahida (Birmingham)

- 09.00 Mechanisms of autoimmunity in ILD
Professor Joanna Porter (London)
- 09.30 Navigating the spectrum of vasculitis in ILD

Professor David Jayne (Cambridge)

10.00 Phenotyping the myositis patient and tailoring management to specific subtypes
Dr Harsha Gunawardena (Bristol)

Learning objectives:

1. Understand range of vasculopathy in systemic sclerosis and novel targets
 2. Spectrum of vasculitis of lung and key management principals, including newer treatments on the horizon
 3. To understand how clinical phenotypes may alter disease outcomes and enable tailored treatment in myositis-spectrum lung disease
-

09.00 – 10.30

SYMPOSIUM

CYSTIC FIBROSIS: NEW INSIGHTS FROM INFECTION TO INFLAMMATION

Chaired by: Professor Robert Gray (Glasgow) and Dr Dawn Lau (Cardiff)

09.00 Covering changing microbial ecology and potential new approaches such as phage therapy
Professor Jo Fothergil (Liverpool)

09.30 What can we learn from large animal models of CF and non-CF Bronchiectasis?
Professor David Stoltz (USA)

10.00 Exploring how understanding non-pathogen driven autoinflammation may be the key to treating residual inflammation in the CF lung following CFTR modulator therapy
Prof Daniel Peckham (Leeds)

Learning objectives:

1. To understand how lung microbiology has changed in CF and how new approaches are needed in anti-microbial therapy.
 2. To learn how pre-clinical models in CF and non-CF muco-obstructive diseases can lead to the development of new treatments.
 3. To determine the role of autoinflammatory pathways in CF and how they might be modulated
-

10.45 – 12.15

SYMPOSIUM

TRANSLATION IN PLEURAL DISEASE – IMPROVING UNDERSTANDING AND TREATMENTS

Chaired by: Professor Gary Lee (Perth) and Selina Tsim (Glasgow)

10.45 Genetic mechanisms in pneumothorax and cystic lung diseases
Professor Stefan Marciniak (Cambridge)

11.15 Macrophage subtypes and cellular immunity in pleural infection

Professor Laura Gleeson (Dublin)

- 11.45 Pleural septation detection, formation and biology – insights from early phase studies
Dr Eihab Bedawi (Oxford)

Learning objectives:

1. To understand the importance and impact of genetic testing in patients with pneumothorax and cystic lung disease
 2. To appraise the current state of the art in macrophage and cellular biology in pleural infection
 3. To understand the current understanding of the meaning and formation of septations in pleural disease
-

10.45 – 12.15

SYMPOSIUM

THE USE OF PHYSIOLOGICAL DATA WITHIN SPECIALIST CLINICS

Chaired by: Dr Vicky Moore (Coventry) and Professor Luke Howard (London)

- 10.45 Specialist Nursing: Physiological data within severe asthma, the path to therapeutics
Katie Borg (Oxford)
- 11.15 Physiotherapy: Physiological data for dysfunctional breathing, a growing evidence base
Chelliah Paramasivan (Cambridge)
- 11.45 Physician Clinics: Physiology data in pulmonary vascular disease, what's new?
Martin Johnson (Scotland)

Learning objectives:

1. To be able to assess the evidence from various physiological tests that provide the pathway to diagnosis and therapeutics in severe asthma. To understand the specialist nursing role in assessing scientific evidence in this area for decision making in CNS clinics
 2. To understand that breathing pattern disorder is becoming a more common and debilitating phenomenon and there is emerging evidence from physiology that can support and aid diagnosis and treatment via physiotherapy
 3. To review what is new alongside current evidence for the use of physiological data in Pulmonary vascular disease, and how this is used in clinical practise for accurate diagnosis
-

10.45 – 12.15

SYMPOSIUM

BTS AUDIT AND QUALITY IMPROVEMENT

Details to be confirmed

12.45 – 13.30

GUEST LECTURE

BTS GRAND CHALLENGE LECTURE

WHY THIS BILL MATTERS: TOBACCO, VAPING AND THE FUTURE OF LUNG HEALTH

Professor Sanjay Agrawal (Leicester)

Introduced by: Professor Elizabeth Sapey (Birmingham)

13.45 – 15.15

SYMPOSIUM

OPTIMISING SLEEP: FUTURE DIRECTIONS FOR TREATING SLEEP DISORDERED BREATHING

Chaired by: Dr Sonya Craig (Liverpool) and Helen May (Manchester)

- 13.45 Gender Differences in Obstructive Sleep Apnoea
Dr Renata Riha (Scotland)
- 14.15 MAD plus CPAP: does combining two established treatments for Obstructive Sleep Apnoea give added benefits?
Dr Tim Quinnell (Cambridge)
- 14.45 Complex Sleep Apnoea and ASV: Evidence, Controversies, and Patient Selection
Professor Esther Schwarz (Zurich)

Learning objectives:

1. To discuss the reasons for delayed diagnoses in women and understand the differences in OSA between men and women and the impact of treatment
 2. To understand the treatment efficacy of CPAP and MADs in comparison to each other and in combination
 3. To understand the indications for ASV and the current evidence in the context of the ADVENT-HF and SERVE-HF trials, with some case examples
-

13.45 – 15.15

SYMPOSIUM

IS THERE A ROLE FOR STEROIDS IN CAP?

Chaired by: Dr Frances Grudzinska (Nottingham) and Dr Meg Coleman (London)

- 13.45 Host immune responses and corticosteroid effects in severe CAP
Professor Thomas Wilkinson (Southampton)
- 14.15 Effect of steroids on mortality in patients with severe community-acquired pneumonia: The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial in context
Professor Anthony Gordon (London)
- 14.45 NICE guidelines in context – steroids in pneumonia
Dr Tm Bewick (Derby)

Learning objectives:

1. Understand how digital technologies are used to monitor paediatric respiratory disease, sleep, and long-term ventilation

2. Evaluate the clinical value of remote monitoring for early detection and personalised management
 3. Identify key challenges and enablers for implementing digital respiratory technologies in routine paediatric practice
-

13.45 – 15.15

SYMPOSIUM

CROSS-DISEASE APPROACHES TO TREATING THE ONSET, EXACERBATION AND PROGRESSION OF CHRONIC LUNG DISEASES

Chaired by: Professor David Lomas (London) and Dr Samantha Walker (ALUK)

- 13.45 New and known pathological pathways as novel targets during the early phases of chronic respiratory disease.
Dr Renata Jurkowska (Cardiff)
- 14.15 Preventing acute microbial-driven exacerbations from destabilising lung function and worsening chronic disease.
Dr Aurelie Crabbe (Belgium)
- 14.45 Opportunities for targeting common cross-disease mechanisms to prevent progression of chronic lung diseases.
Dr Amanda Tatler (Nottingham)

Learning objectives:

1. Explore common pathways and targets, with treatment potential across different stages of chronic respiratory disease, where focused research would accelerate drug discovery
 2. Understand how increased efforts in developing specific research tools are needed to make significant progress towards the development of new treatments, including increased effort towards biomarker development across respiratory diseases
 3. Provide insight into how taking a cross-disease and cross-discipline approach can facilitate collaborations that drive the development of tools (biomarkers) and treatments (drugs) that are truly disease-modifying, and what key elements can drive impactful collaborations
-

15.30 – 17.00

SYMPOSIUM

LUNG CANCER SURVIVORSHIP: RECURRENCE RISK, SECOND PRIMARIES & CHEMOPREVENTION

Chaired by: Dr Liz Fuller (Newcastle) and Dr Alexandra Teagle (Plymouth)

- 15.30 Expanding roles of liquid biopsies for lung cancer: detection, residual disease, surveillance and beyond
Professor Nitzan Rosenfeld (London)
- 16.00 Second primary lung cancers – who is at risk and how long should we follow people up?
Professor Robert Rintoul (Cambridge)

16.30 Preventing the next tumour: are vaccines the answer?
Professor Mariam Jamal-Hanjani (London)

Learning objectives:

1. To recognise the risk of second primary lung cancers in radically treated patients, appreciate potential factors associated with increased risk and be aware of future tools for risk assessment and early detection
 2. To understand the concept of minimal residual disease in lung cancer, its relationship with recurrence and biomarkers to aid surveillance and early diagnosis
 3. To describe current and emerging chemoprevention strategies with a focus on vaccine therapy to prevent or delay the development of second primary lung cancers and tumour recurrence after radical treatment
-

15.30 – 17.00

SYMPOSIUM

OPEN SESSION

Details to be confirmed
